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Colorectal cancer is one of the most common malign tumors in men and women all over the
world. In spite of prevention advances in the last few years, worldwide incidence remains
signiﬁcant, about one million per year.
Objectives: Evaluate rectal cancer survival in patients diagnosed and surgically treated at the
Cancer Reference Unit at Rio Grande do Norte State, Brazil.
Methods: Observational retrospective study composed by 135 patients assisted from 2007
to  2014 at Doctor Luiz Antonio Hospital, Natal, Brazil. Data were collected from the
patient records revision and survival rates were calculated and analyzed by non-parametric
Kaplan–Meier and Wilcoxon tests, respectively. All patients were submitted to surgical treat-
ment, chemotherapy and/or radiotherapy.
Results: Overall survival was 62% in seven years, while disease-free survival in one, three
and ﬁve years was 91.7%, 75.5% and 72.1%, respectively.
Conclusion: Overall survival and disease-free survival remained enhanced until the end of
the study, suggesting that the treatment protocols used in the institution have shown to be
effective.
©  2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This
is  an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail: romualdocorrea@uol.com.br (R.S. Corrêa).
ttp://dx.doi.org/10.1016/j.jcol.2016.04.015
237-9363/© 2016 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sobrevivência  de  câncer  colorretal  em  uma  Unidade  de  Referência  do
Câncer
Palavras-chave:
Câncer colorretal
Cirurgia
Sobrevida
r  e  s  u  m  o
O câncer colorretal é um dos tumores malignos mais comuns em homens e mulheres em
todo  o mundo. Apesar das melhorias na prevenc¸ão nos últimos anos, a incidência global
ainda é expressiva, cerca de um milhão por ano.
Objetivos: Avaliar a sobrevida do câncer de reto nos pacientes diagnosticados e tratados
cirurgicamente na Unidade de Referência do Câncer no Rio Grande do Norte, Brasil.
Métodos: Estudo observacional retrospectivo composto por 135 pacientes, compreendido no
período de 2007 a 2014 no Hospital Dr. Luiz Antônio, Natal, Brasil. Os dados foram coletados
através da revisão de prontuários e as sobrevidas foram calculadas e comparadas utilizando,
respectivamente, os métodos não-paramétricos de Kaplan-Meier e teste de Wilcoxon. Todos
os  pacientes foram submetidos a tratamento cirúrgico, quimioterápico e radioterápico.
Resultados: A sobrevida global foi de 62% em sete anos, sendo a sobrevida livre de doenc¸a
em  um, três e cinco anos de 91,7%, 75,5% e 72,1%, respectivamente.
Conclusão: As sobrevidas global e livre da doenc¸a são elevadas até o encerramento do estudo,
o  que demonstra que os protocolos de tratamento utilizados na instituic¸ão têm se mostrado
eﬁcazes.
©  2016 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. Este
e´  um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://creativecommons.org/Introduction
Colorectal cancer (CRC) is one of the most common malign
tumors in men  and women all over the world. In spite of pre-
vention advances in the last few years, worldwide incidence
remains signiﬁcant (about one million per year). CRC causes
more  than 500,000 deaths per year and is the third most com-
mon  cause of cancer-related deaths.
Brazilian National Cancer Institute estimates for the year
of 2016 in Brazil 16,660 newly diagnosed cases of CRC in men
and 17,620 in women.1
In a regional perspective, excluding non-melanoma skin
tumors, CRC is the fourth most frequent in men  in Brazil-
ian Northeast (5.34/100,000). For women, is the third most
frequent in the same region (8.77/100,000).2
Many  risk factors could contribute to the development of
CRC, as age, diet, genetic factors, predisposing medical con-
ditions and tobacco. People with more  than 40 years age have
higher risk of CRC development, with a peak at 65 years age in
United States. Occidental diet is also a risk factor for colon car-
cinoma due to the high intake of animal fat, exposing colonic
mucosa to high levels of carcinogenic compounds. The occi-
dental low ﬁber diet also promotes a low intestinal transit,
which increases the exposition time to colonic carcinogenic.3
Considering genetic factors, susceptibility to CRC includes
well-deﬁned hereditary syndromes, as Lynch Syndrome often
called hereditary non polyposis colorectal cancer (HNPCC) and
Familial Adenomatous Polyposis (FAP). Therefore, it is rec-
ommended that family history of CRC patients should be
consulted and considered in a risk evaluation.4A variety of surgical approaches, considering location and
extension of the disease, are used to treat the rectal can-
cer primary lesions. These methods include local procedures,licenses/by-nc-nd/4.0/).
as polypectomy, transanal excision and transanal endoscopic
microsurgery, and more  invasive procedures involving trans-
abdominal resection (for example, low anterior resection,
proctectomy with total mesorectal excision and coloanal
anastomosis or abdominoperianal resection).4
Therapy for stage II (T3-4 disease, without lymph node
involvement) or for stage III (positive lymph node without
distant metastasis) rectal cancer often include multimodal
treatment with an association of neoadjuvant/adjuvant
chemotherapy due to the high risk of locoregional recurrence.
This risk is associated with the rectum proximity to pelvic
structures and organs, the absence of serous around the rec-
tum and the technical difﬁculties in having wide surgical
resection margins.4
Survival is an essential part in the study of patients sub-
mitted to colorectal cancer treatment. Statistical analysis as
survival analysis refers to the study of data related to the
time of the event of interest. In other words refers to the time
between one initial event when one patient or object starts one
speciﬁc stage and a ﬁnal event, when this stage is changed.
This time is named life time or failure time and could be since
death as a consequence of disease or a time until one relapse
event.5
About 50–60% of CRC patients will develop metastasis and
80–90% of them will develop resectable metastatic liver dis-
ease. Metastatic disease frequently develops in a metachronic
way after locoregional colorectal cancer treatment and liver is
the most common organ involved.4
TMN staging is an important prognostic factor in CRC.6 It
describes the degree of tumor spread or invasion to nearby
tissues, involvement of regional lymph nodes and presence
of metastasis. In 1930, Dukes7 demonstrated that ganglion
metastasis presence represents an important prognostic fac-
tor related to recurrence and survival. Since then, screening of
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Fig. 1 – Overall survival (solid line) and 95% conﬁdence
intervals (dashed line) estimated by Kaplan–Meier for rectal
value = 0.008) (Fig. 3).
Regarding cancer staging, from 125 patients 18.4% were
classiﬁed as stage I, 29.6% as stage II, 39.2% as stage III and
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ompromised lymph nodes represents a signiﬁcant procedure
n anatomopathological analysis of operatory specimens from
atients submitted to colorectal cancer treatment.6
CRC has a good prognostic when disease is diagnosed at ini-
ial stages. 5-year overall is about 55% in developed countries
nd 40% in developing countries. As occurs to incidence, mor-
ality rates due to CRC are lower in women than in men
orldwide, except in the Caribbean.2
Therefore, the aim of this study is to evaluate survival of
atients with rectum cancer diagnosed and surgically treated
t Cancer Reference Unit of Rio Grande do Norte State from
007 to 2014.
ethods
n observational retrospective study composed by 135
atients was developed at Doctor Luiz Antonio Hospital, Can-
er Reference Unit of Rio Grande do Norte State, Brazil,
rom 2007 to 2014. The study was approved by the Research
thics Committee (REC) from Liga Norteriograndense Contra
 Câncer (Protocol 044/044/2009).
All patients more  than 18 years old with rectal adeno-
arcinoma diagnosed by histopathology and radical surgical
reatment with chemotherapy and/or radiotherapy were
ncluded in the study. Patients with others forms of cancer
ere excluded from this study. During the research, eleven
atients were excluded due the absence of information on
heir records about neoadjuvant treatment, adjuvant treat-
ent and staging.
Data were collected from the records revision considering
he follow information: age, sex, origin, diagnosis, date of diag-
osis (date of biopsy), TNM stage, neoadjuvant treatment, type
f surgical treatment, adjuvant treatment, recurrence, death,
ate of death and cause of death.
All patients were submitted to surgical treatment,
hemotherapy and/or radiotherapy proceeded by members of
he medical staff from Doctor Luiz Antonio Hospital. Cancer
taging was performed according to TNM system from Amer-
can Joint Committee of Cancers (AJCC).
Overall survival was considered starting from the date of
iagnosis, while disease-free survival starting from the date
f surgery. Kaplan–Meier and Wilcoxon non-parametric tests
ere used to estimate and compare survivals, respectively.
vidence results from Wilcoxon test were evaluated consider-
ng signiﬁcance level of 5%. For statistical analysis R software
as used (3.2.2 version).8,9
esults
rom 2007 to 2014 were consulted records from 124 patients.
he mean of age was 67.1 years (±15.87), with 50.3% men  and
9.7% women. Considering neoadjuvant treatment, 3.2% were
ubmitted to chemotherapy, 3.2% to radiotherapy, 37.2% per-
ormed both of them and 56.4% none of them.
Considering surgical procedures, 63.7% were submit-
ed to abdominal retossigmoidectomy, 21.7% to rectal
bdominoperianeal amputation, 6.4% to local resection and
.06% palliative procedures. Considering adjuvant treatment,
1.12% performed chemotherapy, 7.25% radiotherapy, 19.35%cancer data.
performed chemotherapy associated to radiotherapy and
32.25% did not perform any of them.
Cancer recurrence occurred in 25.19% of cases. Data from
patient death reveals that 34.67% died: 74.41% due to cancer,
11.62% due to cancer complications and 13.95% due to others
causes.
Overall survival (Fig. 1) of patients in treatment against rec-
tal cancer was 62% in seven years, while disease-free survival
(Fig. 2) in one, three and ﬁve years was 91.7%, 75.5% and 72.1%,
respectively.
Concerning age groups, we  observed an increased disease-
free survival in patients with age below 50 years and from
70 onwards compared to patients between 50 and 70 years
of age; however, no statistical difference was evidenced (p-
value = 0.441). Nevertheless, overall survival increases as age
rises, as demonstrated when comparing patients with age
below 50 years versus patients with age from 70 onwards (p-Fig. 2 – Disease-free survival (solid line) and 95%
conﬁdence intervals (dashed line) estimated by
Kaplan–Meier for rectal cancer data.
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Fig. 5 – Overall survival estimated by Kaplan–Meier forrectal cancer data comparing age groups.
12.8% as stage IV. Signiﬁcant difference was found between
overall survivals related to cancer staging. However, only
patients from stage I and II differ in a signiﬁcant way consid-
ering disease-free survival (Fig. 4). On the other hand, for
patients classiﬁed as stage IV it was observed a shorter over-
all survival, which is statistically different from others stages
overall survival (Fig. 5).
In contrast, data relative to sex, surgical procedures,
neoadjuvant treatment, adjuvant treatment and recurrence
treatment not showed any statistical difference in overall sur-
vival and disease-free survival.
DiscussionDistribution by sex and mean age of patients diagnosed with
rectum cancer found in our study corresponds to the same
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Fig. 4 – Disease-free survival estimated by Kaplan–Meier for
rectal cancer data comparing cancer staging.rectal cancer data comparing cancer staging.
features found in the literature, as well as the predominance
of retossigmoidectomy as surgical treatment.
A study conducted by Pinho et al.10 revealed a discreet
prevalence in male gender, with a mean age of 61 years
old, and abdominal retossigmoidectomy as the most com-
mon  surgical procedure performed corresponding to 45.3% of
all surgical treatments. Furthermore, it showed that from 89
patients in follow-up, 33 presented disease relapse, similar to
ours results.
After a detailed analysis of data, it was observed that
elderly was the age group most affected by rectal cancer,
regardless of gender, and abdominal retossigmoidectomy the
most common procedure. From all patients included in our
study, one third died due cancer or cancer complications.
According to data analysis from Surveillance Epidemiology
and End Results (SEER), survival in ﬁve years increased from
56.5% in patients diagnosed in the beginning of 1980s to 63.2%
in patients diagnosed in the beginning of 1990s and recently to
64.9%. This survival increase is due mainly to early diagnosis
and treatment. It is known that patient prognosis is highly
dependent on the staging: in ﬁve years the overall survival is
up than 90% to patients classiﬁed as Dukes A, but only 5%
when they are classiﬁed as Dukes D. Unfortunately, only 10%
of patients with this neoplastic disease are diagnosed early
and most of them present advanced disease.11,12
Overall survival of patients submitted to rectal cancer treat-
ment was 62% in seven years, while disease-free survival in
one, three and ﬁve years was 91.7%, 75.5% and 72.1%, respec-
tively. Mussnich et al.13 evaluated overall and clinical and
pathological factors related to rectal adenocarcinoma ad ver-
iﬁed that overall in ﬁve years was 51% and 64 patients (57%)
presented recurrence.
In contrast, a study performed by Downing et al.14 iden-
tiﬁed patients diagnosed with colon and rectal cancer and
classiﬁed them in a perspective of death within one month,
three months and twelve months after diagnosis. Results
from the latter study showed that 11.5% of patients diagnosed
with colon cancer and 5.4% diagnosed with rectal cancer died
2 0 1 6
w
a
e
f
a
r
d
w
(
c
d
o
m
e
t
s
d
t
r
a
a
o
C
A
p
v
e
i
C
T
r
1
1
1
1
1j coloproctol (rio j). 
ithin a month after diagnosis and for both types of cancer
dvanced age, cancer stage at the moment of diagnosis and
mergency presentation were associated with early death. Dif-
erently, our results had not showed any negative inﬂuence of
dvanced age in overall survival of these patients.
According to Phipps et al.,15 comparing with patients that
emained alive at the end of the follow-up or in ﬁve years after
iagnosis, patients that died within ﬁve years after diagnosis
ere more  likely to be male (58% vs. 51%) and to be smokers
64% vs. 59%). Furthermore, mortality due to distal colon can-
er and rectal cancer was signiﬁcantly lower than mortality
ue to proximal colon cancer. Although the lack of evaluation
f colon cancer in the present study, it was found a signiﬁcant
ortality in rectal cancer patients as mentioned by Phipps
t al.15 However, ours data did not revealed difference in mor-
ality between genders.
Considering all surgical procedures, our study did not
howed any signiﬁcant difference in overall survival and
isease-free survival between them. Differently, according
o National Comprehensive Cancer Network (NCCN), recent
etrospectives comparisons between patients submitted to
bdominoperianal resection and patients submitted to low
nterior resection for cancer treatment revealed that former
nes presented worst local control and overall survival.
onclusion
fter a detailed analysis of data, it was observed a signiﬁcant
ercentage of patients free from rectal cancer once overall sur-
ival and disease-free survival remained enhanced until the
nd of the study, suggesting that the treatment protocols used
n the institution have shown to be effective.
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